BPGbio Appoints John Dvor as Executive Vice President, Corporate DevelopmentVeteran life sciences executive and dealmaker to drive strategic partnerships, capital formation, and corporate growth initiatives
BPGbio Wins 2025 AI Drug Development Innovation Award from Biotech Breakthrough AwardsThird consecutive win recognizes BPGbio’s NAi® platform for advancing AI-developed drugs into clinical success
BPGbio Presents Phase 2 Glioblastoma Data on BPM31510 at ESMO 2025BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- BPGbio Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that it will present two posters on its lead investigational drug BPM31510 for Glioblastoma (GBM) in collaboration with Stanford University School of Medicine and other major US cancer centers at the European Society for Medical Oncology (ESMO) Congress 2025 held from October 17 – 20 in Berlin, Germany. BPGbio has completed the phase 2b enrollment of GBM trial late August this year.
BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative DiseaseNew findings challenge the longstanding assumption that postmortem tissue accurately represents the living brain — and can reshape the future of research and drug development for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases
BPGbio Welcomes Sheikh Dr. Khalid Bin Jabor Al Thani as Executive in ResidenceDistinguished cancer leader to advise BPGbio leadership on acceleration of NAi platform globally and BPM 31510 oncology franchise for Precision Oncology Initiatives
BPGbio Appoints Veteran Clinical and Commercial Leader Dr. Brian Berman as Interim Chief Medical OfficerCompany strengthens its late-stage trials with enhanced clinical and commercial leadership for its BPM31510 programs
BPGbio Sponsors MitoAction Energy Walk at Boston’s Franklin Park Zoo on September 27th, 2025Company honored in its commitment to patients and families living with mitochondrial disease; invites the community to walk with BPGbio colleagues and MitoAction
BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM)BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- BPGbio Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced the completion of enrollment in its Phase IIb trial of BPM31510-IV, in combination with Vitamin K1, for patients with newly diagnosed glioblastoma multiforme (GBM).
BPGbio Presents Advances in Spatial Omics Technology and Targeted Protein Degradation Insights at ASMS 2025Presentations highlight cutting-edge research in mitochondrial and neurodegeneration medicine, neurodegeneration, immuno-oncology, and E2-targeted protein degradation using next-generation mass spectrometry
BPGbio Announces Presentation of Preliminary Clinical Data of Investigational BPM31510 for Primary CoQ10 DeficiencyBOSTON, June 18, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that Vijay Modur, MD, Ph.D., the company’s Chief Medical Officer will present on Friday, June 20, clinical update from ongoing compassionate use treatment with intravenous BPM31510 in patients with Primary CoQ10 Deficiency (PCQD) at the United Mitochondrial Disease Foundation’s Mitochondrial Medicine Conference 2025 taking place in St. Louis, MO.
BPGbio CEO Dr. Niven R. Narain Named to The Medicine Maker Power List 2025Recognition highlights Narain’s impact in AI-driven drug discovery and biology-first innovation to the biopharma industry
BPGbio Highlights Groundbreaking Data on BPM31510 for Mitochondrial Diseases at the Inaugural Mitochondrial Transplantation and Next Generation Therapeutics ConferenceAdvanced Spatial Quinomics Study Reveals Novel Insights into the Therapeutic Impact of BPM31510, Being Studied as a Potential Treatment for Primary CoQ10 Deficiency and Other Mitochondrial Diseases
BPGbio Presents New Research on Tumor Metabolism, Immunotherapy, and Diagnostics at AACR Annual Meeting 2025Company’s presentations highlight the power of mitochondrial medicine and protein homeostasis technologies to address aggressive cancers including glioblastoma and pancreatic cancer
BPGbio's Lipidomics Expertise Powers Groundbreaking Discovery of Lipid-Rich Cartilage Published in Science
BPGbio, a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, is thrilled to announce its contribution to a groundbreaking study published in the January 10 issue of Science. This study describes the discovery of a novel lipid-rich tissue type, lipocartilage, which exhibits unique skeletal support properties distinct from classical cartilage rich in extracellular matrix proteins. This discovery has transformative implications for regenerative medicine and reconstructive surgery, offering new pathways for personalized cartilage tissue repair and replacement.
BPGbio Announces Publication in Scientific Reports on Validation of Novel Diagnostic Biomarker Panel for Parkinson’s Disease
BPGbio, a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, announced today the publication of a significant, multi-year research effort titled “Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson’s disease biomarker panel” in Scientific Reports.
